CGBIO Receives FDA IDE Approval for NOVOSIS PUTTY, Advancing Toward U.S. Market Entry
- The bone graft incorporating rhBMP-2 has received FDA IDE approval for a pivotal clinical trial in spinal fusion - Positioned for global expansion in $750M spinal bone graft market SEOUL, South Korea, April 24, 2025 /PRNewswire/ -- CGBIO(CEO Hyun...
Daewoong Pharmaceutical Captivates Global Experts at AMWC-SEA with 'Nabolift,' Redefining Toxin Treatments
- At "AMWC SEA 2024," one of the world's top three aesthetic medicine congresses, the Nabota booth attracted over 500 visitors. - Educated over 300 Thai physicians on the innovative "Nabolift" technique through the "Nabota Master Class (NMC)." -...
HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion of a First-in-Human Study for Potential Disease-Modifying Therapy for Parkinson's Disease
HL192 (ATH-399A) was well tolerated with no major safety issues in any of the 76 participants. No serious treatment related adverse events were reported and such findings were proportional between placebo and dosed groups. PK results support once a...
